SINGAPORE, Jan. 28, 2026 — (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical-stage biopharmaceutical firm dedicated to leveraging its proprietary technologies to develop new, affordable donor-derived cell-based immunotherapies for treating a wide array of cancers—encompassing both blood and solid tumors—issued a statement today to address recent public remarks containing inaccurate and misleading claims about the Company’s research initiatives, clinical advancements, and operations.
CytoMed strongly refutes these baseless claims. Certain publicly circulating statements misrepresent the Company’s scientific focus, development status, and regulatory position. For details on the Company’s progress, please refer to its recent announcements.
CytoMed’s research centers on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, grounded in well-established immunological science. The Company’s leading CAR γδ T cell program has secured regulatory approval to initiate a first-in-human (FIH) clinical trial, which is currently underway at Singapore’s National University Hospital (NUH). This clinical activity adheres to all applicable regulatory and ethical requirements.
Other programs, including iPSC-derived γδ NKT cell candidates, remain in preclinical development. CytoMed does not assert that any of its therapeutic candidates have been approved for commercial use or clinically validated beyond their current development stage.
Claims regarding CytoMed’s regulatory standing, manufacturing capabilities, governance, or financial transparency that conflict with the above facts are either inaccurate, taken out of context, or intended to impact the Company’s share price. The Company operates in compliance with relevant regulations and follows development practices suitable for its stage.
CytoMed remains dedicated to responsibly advancing its pipeline and sharing accurate, timely information through official Company disclosures. The Company retains the right to take appropriate measures to address the spread of false or misleading information that could harm its reputation or affect stakeholders.
Shareholders may contact the individual below for clarification.
About CytoMed Therapeutics Limited (CytoMed)
Established in 2018, CytoMed was spun off from Singapore’s Agency for Science, Technology and Research (A*STAR), the public sector’s leading research and development agency. CytoMed is a clinical-stage biopharmaceutical company focused on utilizing its licensed proprietary technologies—gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell—to create novel cell-based allogeneic immunotherapies for treating various human cancers. The development of these new technologies is inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in applying the CAR-T approach to solid tumor treatment. For more information, visit and follow us on Twitter (“X”) @CytomedSG, LinkedIn, and Facebook.
Forward-Looking Statements
This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements cover plans, objectives, goals, strategies, future events or performance, underlying assumptions, and other non-historical statements. When the Company uses terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions not solely tied to historical matters, it is making forward-looking statements. These statements do not guarantee future performance and involve risks and uncertainties that could cause actual results to differ significantly from the Company’s expectations. These risks and uncertainties include, but are not limited to: the Company’s plans to develop and commercialize product candidates; the start, timing, progress, and outcomes of current and future preclinical studies, clinical trials, and R&D programs; estimates of expenses, future revenue, capital needs, and requirements for additional financing; the ability to acquire or license additional product candidates on reasonable terms; the ability to establish and maintain collaborations or secure additional funding; assumptions underlying or related to the foregoing; and other risks detailed in the Company’s SEC filings. For these reasons, investors are advised not to place undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the Company’s SEC filings, available for review at www.sec.gov. The Company assumes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in jurisdictions where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
